Menu
Recruiting NCT07308015

Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator

Phase IV Interventional Rhinitis Sicca

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Physiological seawater adjustable nasal irrigator, Sodium hyaluronate adjustable nasal irrigator.
Who it may be relevant to
Registry conditions: Rhinitis Sicca. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

To observe the therapeutic effect of sodium hyaluronate adjustable nasal irrigator on various types of rhinitis sicca and compare it with the therapeutic effect of the commonly used physiological seawater nasal spray in clinical practice.

Interventions

  • Drug Physiological seawater adjustable nasal irrigator
    Nasal spray of Physiological seawater.
  • Drug Sodium hyaluronate adjustable nasal irrigator
    Nasal spray of Sodium hyaluronate

Primary outcome measures

  • Visual Analogue Scale (VAS) [Time frame: Two weeks after the treatment]
Secondary outcome measures (1)
  • Nasal endoscopy examination score [Time frame: Two weeks after the treatment]

Eligibility criteria

Inclusion criteria

  • Symptoms: Dry nose sensation, little and thick nasal discharge, nosebleeds, itchy nasal cavity, and dryness in the nasopharynx. Physical signs: Nasal endoscopy often reveals dry and congested nasal mucosa, which appears grayish-white or dark red, losing its normal luster. There are often dry, thick secretions, scabs or blood scabs on it. The surface of the nasal mucosa is eroded and ulcers occur. The mucosal lesions are most obvious in the anterior part of the nasal cavity. A diagnosis can be made if one or more of the above symptoms and signs are present.

Exclusion criteria

  • Those with dry rhinitis and chronic inflammation of the lower respiratory tract.
  • Those confirmed by examination to be caused by certain latent lesions in the mouth, nose, throat, esophagu.s, neck or the whole body
  • Those who have used drugs for treating dry rhinitis or other medications within the past 30 days.
  • Pregnant or lactating women.
  • Those who are allergic to this medicine.
  • Those with severe cardiovascular, liver, kidney and hematopoietic system diseases, etc.
  • Mentally ill patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

China · 1 center
  • China-Japan Union Hospital of Jilin University — Changchun

Identifiers

NCT: NCT07308015 · 2025052906

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗